Abstract:Key Points: No correlation was observed between pruritus severity and serum phosphate or response to placebo or difelikefalin in patients with CKD-associated pruritus undergoing hemodialysis.Difelikefalin improved itch versus placebo irrespective of baseline serum phosphate. Background: CKD-associated pruritus (CKD-aP) has historically been associated with elevated serum phosphate (sP). Difelikefalin is a novel antipruritic agent approved for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis. This post hoc analysis used data from phase 3 difelikefalin studies (KALM-1, KALM-2, and open-label Study 3105) to assess the role of sP in the pathogenesis of CKD-aP and whether difelikefalin ameliorates CKD-aP in patients with and without elevated sP. Methods: Patients with moderate-to-severe CKD-aP undergoing hemodialysis with baseline sP data were included in the analysis (KALM-1 and KALM-2, n=845; Study 3105, n=220). Assessments included correlation between 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) score and sP. Results: In KALM-1 and KALM-2, baseline characteristics in the overall population were similar between patients with sP ≤5.5 and >5.5 mg/dl; no significant correlation was observed between WI-NRS and sP at baseline or in week 12. In patients receiving placebo, no correlation was observed between WI-NRS and sP at baseline or between their change from baseline to week 12 (all P < 0.05). Clinically meaningful (≥3-point) reductions from baseline to week 12 in WI-NRS scores were reported by more patients receiving placebo with baseline sP ≤5.5 mg/dl than >5.5 mg/dl (least squares mean 37.2% versus 27.4%; odds ratio [95% confidence interval], 0.63 [0.41 to 0.97]; P = 0.04). A greater proportion of patients treated with difelikefalin achieved a ≥3-point WI-NRS reduction from baseline to week 12 versus placebo and was similar between sP ≤5.5 and >5.5 mg/dl subgroups (least squares means 51.1% versus 57.6% [P = 0.20]). No significant relationships between sP and WI-NRS in patients receiving difelikefalin were identified in Study 3105 at any time point. Conclusions: No correlation was observed between pruritus severity and sP or response to placebo or difelikefalin in patients with CKD-aP undergoing hemodialysis. Difelikefalin improved itch versus placebo irrespective of baseline sP.

Cost effectiveness of difelikefalin for the treatment of patients with chronic kidney disease-associated pruritus undergoing hemodialysis in Italy

Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis

Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial

Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis

Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program

A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus

Difelikefalin for pruritus associated with renal disease

Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease–Associated Pruritus

Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a post hoc analysis of phase 3 data using the Skindex-10 questionnaire

Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2

Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review

Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis

Difelikefalin: First Approval

Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus

Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies

Chronic kidney disease-associated pruritus (CKD-aP) is associated with worse quality of life and increased healthcare utilization among dialysis patients

Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients

Diagnostic et prise en charge du prurit associé à la maladie rénale chronique chez les patients hémodialysés

Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis

The role of blood purification therapies in the treatment of chronic kidney disease-associated pruritus: a systematic review

Impact of pruritus in patients undergoing hemodialysis in Italy: a patient-based survey